1. Volume 8, Issue 4, Pages 334-344 (April 2009)
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient- preference trial 
John Collinge, MD, Michele Gorham, RN, Fleur Hudson, BA, Angus Kennedy, MD, Geraldine Keogh, Suvankar Pal, MRCP, Martin Rossor, MD, Peter Rudge, FRCP, Durre Siddique, PhD, Moira Spyer, PhD, Dafydd Thomas, MD, Sarah Walker, PhD, Tom Webb, BSc, Steve Wroe, MD, Janet Darbyshire, FRCP 
The Lancet Neurology 
Volume 8, Issue 4, Pages (April 2009)
DOI: /S (09)
Copyright © 2009 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*Relative with symptomatic inherited prion disease or recipient of blood transfusion. †From September, 2001–June, 2002, six patients received open-label quinacrine in an initial pilot study, and from August, 2002, to March, 2004, 17 more were offered quinacrine or no quinacrine in an extended pilot study (total 23 patients). ‡One originally chose not to take quinacrine but later agreed to randomisation 9 weeks after enrolment and was allocated immediate quinacrine.
The Lancet Neurology 2009 8, DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

3. Figure 2 Quinacrine use after initiation
The Lancet Neurology 2009 8, DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

4. Figure 3
Survival
Unadjusted survival from enrolment (A). Survival from enrolment by baseline Rankin score (B). Survival from first symptoms by type of human prion disease (C).
The Lancet Neurology 2009 8, DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions